HCAT Q1 Earnings Call: Ignite Platform Drives Client Growth Amid Funding Uncertainty

Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.3% year on year to $79.41 million. On the other hand, next quarter’s revenue guidance of $80.5 million was less impressive, coming in 3.1% below analysts’ estimates. Its non-GAAP profit of $0.01 per share was in line with analysts’ consensus estimates.

Is now the time to buy HCAT? Find out in our full research report (it’s free).

StockStory’s Take

Health Catalyst’s first quarter results reflected the company’s ongoing transition from its legacy DOS platform to the newer Ignite platform, which management cited as a key driver of both technology revenue growth and improved margins. CEO Dan Burton highlighted that 10 net new platform clients were added in the quarter, with approximately two-thirds expanding from existing application relationships—signaling the success of Health Catalyst’s cross-sell strategy. The Ignite platform’s modularity and lower entry price point were credited with streamlining the sales process and shortening sales cycles, especially in an environment marked by cautious health system spending and funding uncertainties. Burton noted that Ignite’s higher gross margin profile and greater mix of technology revenue versus professional services are central to Health Catalyst’s strategy, stating, “Ignite is a more profitable platform than DOS with approximately 70% gross margins compared to approximately 60% for DOS.”

Looking ahead, Health Catalyst’s full-year outlook is shaped by continued migration to the Ignite platform, expectations for steady net new client additions, and ongoing market headwinds related to Medicaid and research funding. Management reiterated a target of 40 net new platform clients for the year, anticipating that most Ignite migrations will be completed by mid-2026. CFO Jason Alger acknowledged that delays in Health Information Exchange client implementations and funding uncertainties could shift some revenue recognition into the second half of the year, but expressed confidence in the company’s robust pipeline and Ignite’s resilience. Burton emphasized that Ignite’s flexibility and ability to deliver tangible ROI position Health Catalyst to “meet clients where they are,” even as some organizations delay purchasing decisions. The company also expects operating leverage improvements from recent cost reductions and offshoring initiatives, contributing to its profit margin targets.

Key Insights from Management’s Remarks

Management attributed first quarter performance to Ignite’s ability to drive incremental technology revenue, expand cross-sell opportunities, and accelerate client wins, even as funding uncertainties persisted in segments like Health Information Exchanges and Life Sciences.

• Ignite platform momentum: The Ignite platform enabled Health Catalyst to add 10 net new platform clients, with two-thirds coming from existing application clients. Management highlighted that Ignite’s lower entry price and modular design have shortened sales cycles and increased conversion rates, especially in a cautious healthcare spending environment.
• Shift to technology revenue: New Ignite deals are contributing to a more favorable revenue mix, with approximately 80% of new client spend directed toward technology rather than professional services. This mix shift is expected to support higher gross margins and more predictable recurring revenue.
• Mid-market expansion via Spark: The company made early progress with Ignite Spark, a solution tailored for mid-sized health systems that have traditionally lacked access to enterprise-grade analytics. Management believes this market segment represents a significant growth opportunity unlocked by Ignite’s modularity and pricing flexibility.
• Client migration impacts: The ongoing migration from DOS to Ignite has led to some clients reducing total spend, as Ignite’s lower cost structure enables savings. While this creates a near-term headwind for dollar-based retention, management expects it to subside after most migrations are completed by late 2026.
• Acquisitions and product integration: Recent acquisitions, including patient engagement and cybersecurity solutions, are being integrated into the Ignite platform, broadening Health Catalyst’s offerings and supporting cross-sell opportunities. Early wins combining these assets with Ignite were noted as evidence of the portfolio’s growing value proposition.

Drivers of Future Performance

Health Catalyst’s forward outlook is anchored in Ignite’s continued adoption, the pace of client migrations, and the company’s ability to navigate ongoing healthcare funding uncertainties while maintaining margin discipline.

• Ignite migration pace: Management expects to complete about two-thirds of Ignite platform client migrations by year-end and most by mid-2026. The speed of these transitions will impact technology revenue growth and margin expansion, as Ignite offers higher gross margins than DOS.
• Funding environment risks: Delays in Health Information Exchange and Life Sciences deals, as well as uncertainties around Medicaid and research funding, could impact the timing of new client wins and revenue recognition. Management has factored these risks into guidance, emphasizing Ignite’s lower price point and ROI as mitigating factors.
• Cost efficiency initiatives: The company is pursuing operating leverage through offshoring, particularly in R&D and SG&A, and recently executed a reduction in force. These actions are expected to lower operating expenses as a percentage of revenue, supporting EBITDA margin improvement over the next several quarters.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace of Ignite platform migrations and net new platform client additions; (2) resolution of funding uncertainties impacting Health Information Exchange and Life Sciences segments; and (3) the impact of cost efficiency measures on operating margins. Progress on cross-selling recently acquired products and successful mid-market expansion will also be key indicators of execution.

Health Catalyst currently trades at a forward price-to-sales ratio of 0.8×. At this valuation, is it a buy or sell post earnings? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.